<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ksma</journal-id><journal-title-group><journal-title xml:lang="ru">Кубанский научный медицинский вестник</journal-title><trans-title-group xml:lang="en"><trans-title>Kuban Scientific Medical Bulletin</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1608-6228</issn><issn pub-type="epub">2541-9544</issn><publisher><publisher-name>Kuban State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.25207/1608-6228-2023-30-1-98-108</article-id><article-id custom-type="elpub" pub-id-type="custom">ksma-2852</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. МЕДИКО-БИОЛОГИЧЕСКИЕ НАУКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. MEDICAL AND BIOLOGICAL SCIENCES</subject></subj-group></article-categories><title-group><article-title>Клинико-морфологический анализ эффективности внутрибрюшинного применения озона при экспериментальном колите: доклиническое рандомизированное исследование</article-title><trans-title-group xml:lang="en"><trans-title>Clinical and Morphological Analysis of Efficacy of Intraperitoneal Ozone Application in Experimental Colitis: Preclinical Randomized Experimental Study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6487-9083</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Осиков</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Osikov</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Осиков Михаил Владимирович — доктор медицинских наук, профессор; заведующий кафедрой патологической физиологии Южно-Уральский ГМУ; руководитель научного отдела Челябинская ОКБ.</p><p>Ул. Воровского, д. 64, Челябинск, 454048; Ул. Воровского, д. 70, г. Челябинск, 454048</p></bio><bio xml:lang="en"><p>Michail V. Osikov — Dr. Sci. (Med.), Prof., Head of Department of Morbid Physiology, South Ural SMU; Head of Research and Development Unit, Chelyabinsk RCH.</p><p>Vorovskogo str., 64, Chelyabinsk, 454048; Vorovskogo str., 70, Chelyabinsk, 454048</p></bio><email xlink:type="simple">prof.osikov@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8403-8599</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кайгородцева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kaygorodtceva</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кайгородцева Наталья Васильевна — ассистент кафедры патологической физиологии Южно-Уральский ГМУ; врач—анестезиолог-реаниматолог отделения реанимации и интенсивной терапии № 3 Челябинская ОКБ.</p><p>Ул. Воровского, д. 64, Челябинск, 454048; Ул. Воровского, д. 70, г. Челябинск, 454048</p></bio><bio xml:lang="en"><p>Natal’ya V. Kaygorodtceva — Assistant, Department of Morbid Physiology, South Ural SMU; Intensivist, Intensive Care Unit No. 3, Chelyabinsk RCH.</p><p>Vorovskogo str., 64, Chelyabinsk, 454048; Vorovskogo str., 70, Chelyabinsk, 454048</p></bio><email xlink:type="simple">nkaigorodceva@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4046-2424</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бойко</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Boyko</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бойко Маргарита Сергеевна — ассистент кафедры патологической физиологии.</p><p>Ул. Воровского, д. 64, Челябинск, 454048</p></bio><bio xml:lang="en"><p>Margarita S. Boyko — Assistant, Department of Morbid Physiology.</p><p>Vorovskogo str., 64, Chelyabinsk, 454048</p></bio><email xlink:type="simple">ri-tochka9@list.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3155-6605</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Астахова</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Astachova</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Астахова Людмила Витальевна — руководитель отдела поисковых исследований.</p><p>Пр-кт Победы, д. 287, г. Челябинск, 454136</p></bio><bio xml:lang="en"><p>Lyudmila V. Astachova — Head of Exploratory Research Unit.</p><p>Prospekt Pobedy, 287, Chelyabinsk, 454136</p></bio><email xlink:type="simple">bonikva@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Южно-Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации; Государственное бюджетное учреждение здравоохранения «Челябинская областная клиническая больница»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Ural State Medical University; Chelyabinsk Regional Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Южно-Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Государственное бюджетное учреждение здравоохранения «Многопрофильный центр лазерной медицины»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Multidisciplinary Center for Laser Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>18</day><month>02</month><year>2023</year></pub-date><volume>30</volume><issue>1</issue><fpage>98</fpage><lpage>108</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Осиков М.В., Кайгородцева Н.В., Бойко М.С., Астахова Л.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Осиков М.В., Кайгородцева Н.В., Бойко М.С., Астахова Л.В.</copyright-holder><copyright-holder xml:lang="en">Osikov M.V., Kaygorodtceva N.V., Boyko M.S., Astachova L.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://ksma.elpub.ru/jour/article/view/2852">https://ksma.elpub.ru/jour/article/view/2852</self-uri><abstract><sec><title>Введение</title><p>Введение. Воспалительные заболевания кишечника — болезнь Крона и язвенный колит — хронические заболевания пищеварительного тракта, поражающие молодое трудоспособное население. Альтернативой применения базисной терапии (5-аминосалициловая кислота) при воспалительных заболеваниях кишечника является применение озона, который обладает противовоспалительными, иммуномодулирующими, антибактериальными свойствами, в терапевтических концентрациях он лишен побочных эффектов.</p></sec><sec><title>Цель исследования</title><p>Цель исследования: провести клинико-морфологический анализ эффективности применения озона при экспериментальном колите.</p></sec><sec><title>Методы</title><p>Методы. Исследование выполнено на 73 самцах крыс массой 200–250 г линии Wistar. Методом простой рандомизации животных делили на четыре группы. Исследования проводили на вторые, четвертые и шестые сутки. Оксазолон-индуцированный колит моделировали в два этапа с помощью 3% спиртового раствора оксазолона. Озонокислородную смесь получали на установке «УОТА-60–01» («Медозон», Россия). Ректальные суппозитории с 5-аминосалициловой кислотой готовили на основе ректальных суппозиториев «Салофальк». Клинический статус оценивали ежедневно в соответствии со шкалой индекса активности болезни (disease activity index, DAI). Морфологическую оценку фрагментов тканей очага повреждения толстой кишки проводили на микроскопе PrimoStar (CarlZeiss, Германия). Повреждение тканей толстой кишки оценивали с помощью индекса повреждения тканей (tissue damage index, TDI). Статистическую обработку результатов проводили с использованием SPSS Statistics 19 (IBM, США).</p></sec><sec><title>Результаты</title><p>Результаты. Клинико-морфологическая картина поражения толстой кишки при оксазолон-индуцированном колите на вторые, четвертые и шестые сутки соответствует изменениям при воспалительных заболеваниях кишечника у человека. Ежедневные внутрибрюшинные инсуффляции озона в дозе 0,05 мг/кг при оксазолон-индуцированном колите приводят к частичному восстановлению индекса DAI, снижению в очаге повреждения количества нейтрофилов, эозинофилов, гистиоцитов, фибробластов, уменьшению диаметра язвенного дефекта и индекса TDI. Эффекты при оксазолон-индуцированном колите внутрибрюшинных инсуффляций озона по сравнению с эффектами применения каждые 12 ч ректальных суппозиториев с 50 мг 5-аминосалициловой кислоты менее выражены в отношении индекса DAI на четвертые сутки; в отношении количества эозинофилов, плазмоцитов, гистиоцитов — на вторые, четвертые и шестые; в отношении лимфоцитов — на шестые сутки.</p></sec><sec><title>Заключение</title><p>Заключение. Клинико-морфологическая картина поражения толстой кишки при озон-индуцированном колите соответствует изменениям при воспалительных заболеваниях кишечника у человека. Положительный эффект озона при озон-индуцированном колите обусловлен его противовоспалительными свойствами за счет активации Nrf2, антиоксидантными свойствами за счет ингибирования Keap1.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Inflammatory bowel diseases — Crohn’s disease and ulcerative colitis — are chronic gastrointestinal diseases affecting young people of working age. An alternative to basic therapy (5-aminosalicylic acid) for inflammatory bowel disease is the use of ozone, which has anti-inflammatory, immunomodulatory, antibacterial properties and no side effects in therapeutic concentrations. Objective. To perform clinical and morphological analysis of efficacy of intraperitoneal ozone application in experimental colitis.</p></sec><sec><title>Methods</title><p>Methods. The study was conducted on 73 male Wistar rats weighing 200-250 g. The animals were divided into four groups by simple randomization. Check studies were performed on the second, fourth and sixth days. Oxazolone-induced colitis was simulated in two stages using a 3%-alcohol oxazolone solution. Ozone-acid mixture was obtained on “UOTA-60-01” unit (“Medozone”, Russia). Rectal suppositories with 5-aminosalicylic acid were prepared on the basis of rectal suppositories “Salofalk”. Clinical status was assessed daily according to the disease activity index (DAI) scale. Morphological evaluation of colon lesion tissue fragments was carried out using a PrimoStar microscope (CarlZeiss, Germany). Colon tissue damage was assessed using tissue damage index (TDI). Statistical analysis was conducted with SPSS Statistics 19 (IBM, USA).</p></sec><sec><title>Results</title><p>Results. Clinical and morphological picture of the large intestine lesion in oxazolone-induced colitis on days 2, 4 and 6 is consistent with the changes typical of inflammatory bowel disease in humans. Daily intraperitoneal insufflation of ozone at a dose of 0.05 mg/kg in oxazolone-induced colitis leads to partial restoration of DAI, reduction in neutrophils, eosinophils, histiocytes, and fibroblasts in the lesion, as well as to a decrease in ulcerous defect diameter and TDI. The effects of intraperitoneal insufflations of ozone in oxazolone-induced colitis as compared to rectal suppositories with 50 mg of 5-aminosalicylic acid every 12 hours were less marked for the DAI index on day 4; for the number of eosinophils, plasma cells, histiocytes — on day 2, 4 and 6; for lymphocytes — on day 6.</p></sec><sec><title>Conclusion</title><p>Conclusion. Clinical and morphological picture of the large intestine lesion in ozone-induced colitis correlates with the changes typical of inflammatory bowel disease in humans. The positive effect of ozone in ozone-induced colitis was driven by its anti-inflammatory properties through the activation of Nrf2 and by its antioxidant properties through the inhibition of Keap1.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>экспериментальный колит</kwd><kwd>озон</kwd><kwd>индекс активности болезни</kwd><kwd>морфология</kwd><kwd>5-аминосалициловая кислота</kwd></kwd-group><kwd-group xml:lang="en"><kwd>experimental colitis</kwd><kwd>ozone</kwd><kwd>disease activity index</kwd><kwd>morphology</kwd><kwd>5-aminosalicylic acid</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">исследование не имело спонсорской поддержки</funding-statement><funding-statement xml:lang="en">The authors declare that no funding was received for this study</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Игнатьева В.И., Авксентьева М.В., Омельяновский В.В., Деркач Е.В. Социально-экономическое бремя воспалительных заболеваний кишечника в Российской Федерации. Профилактическая медицина. 2020; 23(2): 19–25. DOI: 10.17116/profmed20202302119</mixed-citation><mixed-citation xml:lang="en">Ignatieva V.I., Avxentyeva M.V., Omel’ianovskiĭ V.V., Derkach E.V.. Socioeconomic burden of inﬂ ammatory bowel disease in the Russian Federation. Proﬁ lakticheskaya Meditsina. 2020; 23(2): 19–25 (In Russ.). DOI: 10.17116/profmed20202302119</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Биннатли Ш.А., Алешин Д.В., Куликов А.Э., Романов Р.И. Качество жизни пациентов, оперированных по поводу язвенного колита (обзор литературы). Колопроктология. 2019; 18(1(67)): 89–100. DOI: 10.33878/2073-7556-2019-18-1-89-100</mixed-citation><mixed-citation xml:lang="en">Binnatli S.A., Aleshin D.V., Kulikov A.E., Romanov R.I. Quality life of patients operated for ulcerative colitis. Koloproktologia. 2019; 18(1(67)): 89–100 (In Russ.). DOI: 10.33878/2073-7556-2019-18-1-89-100</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Omenetti S., Pizarro T.T. The Treg/Th17 Axis: A Dynamic Balance Regulated by the Gut Microbiome. Front. Immunol. 2015; 6: 639. DOI: 10.3389/ﬁmmu.2015.00639</mixed-citation><mixed-citation xml:lang="en">Omenetti S., Pizarro T.T. The Treg/Th17 Axis: A Dynamic Balance Regulated by the Gut Microbiome. Front. Immunol. 2015; 6: 639. DOI: 10.3389/ﬁmmu.2015.00639</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ситкин СИ, Вахитов ТЯ, Демьянова ЕВ. Микробиом, дисбиоз толстой кишки и воспалительные заболевания кишечника: когда функция важнее таксономии. Альманах клинической медицины. 2018; 46(5): 396–425. DOI: 10.18786/20720505-2018-46-5-396-425.</mixed-citation><mixed-citation xml:lang="en">Sitkin S.I., Vakhitov T.Ya., Demyanova E.V. Microbiome, gut dysbiosis and inﬂ ammatory bowel disease: That moment when the function is more important than taxonomy. Almanac of Clinical Medicine. 2018; 46(5): 396–425 (In Russ.). DOI: 10.18786/20720505-2018-46-5-396-425.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">GBD 2017 Inﬂ ammatory Bowel Disease Collaborators. The global, regional, and national burden of inﬂ ammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. Gastroenterol. Hepatol. 2020; 5(1): 17–30. DOI: 10.1016/S2468-1253(19)30333-4</mixed-citation><mixed-citation xml:lang="en">GBD 2017 Inﬂ ammatory Bowel Disease Collaborators. The global, regional, and national burden of inﬂ ammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. Gastroenterol. Hepatol. 2020; 5(1): 17–30. DOI: 10.1016/S2468-1253(19)30333-4</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ryan F.J., Ahern A.M., Fitzgerald R.S., Laserna-Mendieta E.J., Power E.M., Clooney A.G., O’Donoghue K.W., McMurdie P.J., Iwai S., Crits-Christoph A., Sheehan D., Moran C., Flemer B., Zomer A.L., Fanning A., O’Callaghan J., Walton J., Temko A., Stack W., Jackson L., Joyce S.A., Melgar S., DeSantis T.Z., Bell J.T., Shanahan F., Claesson M.J. Colonic microbiota is associated with inﬂ ammation and host epigenomic alterations in inﬂ ammatory bowel disease. Nat. Commun. 2020; 11(1): 1512. DOI: 10.1038/s41467-020-15342-5</mixed-citation><mixed-citation xml:lang="en">Ryan F.J., Ahern A.M., Fitzgerald R.S., Laserna-Mendieta E.J., Power E.M., Clooney A.G., O’Donoghue K.W., McMurdie P.J., Iwai S., Crits-Christoph A., Sheehan D., Moran C., Flemer B., Zomer A.L., Fanning A., O’Callaghan J., Walton J., Temko A., Stack W., Jackson L., Joyce S.A., Melgar S., DeSantis T.Z., Bell J.T., Shanahan F., Claesson M.J. Colonic microbiota is associated with inﬂ ammation and host epigenomic alterations in inﬂ ammatory bowel disease. Nat. Commun. 2020; 11(1): 1512. DOI: 10.1038/s41467-020-15342-5</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Schirmer M., Garner A., Vlamakis H., Xavier R.J. Microbial genes and pathways in inﬂ ammatory bowel disease. Nat. Rev. Microbiol. 2019; 17(8): 497–511. DOI: 10.1038/s41579-019-0213-6</mixed-citation><mixed-citation xml:lang="en">Schirmer M., Garner A., Vlamakis H., Xavier R.J. Microbial genes and pathways in inﬂ ammatory bowel disease. Nat. Rev. Microbiol. 2019; 17(8): 497–511. DOI: 10.1038/s41579-019-0213-6</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">He C., Wang H., Liao W.D., Peng C., Shu X., Zhu X., Zhu Z.H. Characteristics of mucosa-associated gut microbiota during treatment in Crohn’s disease. World J. Gastroenterol. 2019; 25(18): 2204–2216. DOI: 10.3748/wjg.v25.i18.2204</mixed-citation><mixed-citation xml:lang="en">He C., Wang H., Liao W.D., Peng C., Shu X., Zhu X., Zhu Z.H. Characteristics of mucosa-associated gut microbiota during treatment in Crohn’s disease. World J. Gastroenterol. 2019; 25(18): 2204–2216. DOI: 10.3748/wjg.v25.i18.2204</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Weisshof R., El Jurdi K., Zmeter N., Rubin D.T. Emerging Therapies for Inﬂ ammatory Bowel Disease. Adv. Ther. 2018; 35(11): 1746–1762. DOI: 10.1007/s12325-018-0795-9</mixed-citation><mixed-citation xml:lang="en">Weisshof R., El Jurdi K., Zmeter N., Rubin D.T. Emerging Therapies for Inﬂ ammatory Bowel Disease. Adv. Ther. 2018; 35(11): 1746–1762. DOI: 10.1007/s12325-018-0795-9</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Маев И.В., Андреев Д.Н. Таргетная терапия воспалительных заболеваний кишечника: реалии и перспективы. Медицинский Совет. 2018; 6: 114–118. DOI: 10.21518/2079-701X2018-6-114-118</mixed-citation><mixed-citation xml:lang="en">Maev I.V., Andreev D.N. Targeted therapy of inflammatory bowel diseases: realities and prospects. Medical Council. 2018; 6: 114–118 (In Russ.). DOI: 10.21518/2079-701X2018-6-114-118</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ner J., Lomba E., Karam A.M., De Almeda Reis S.R., Teixeira Marchionni A., Pexoto Meidrado A. Ozone therapy inﬂ uence in the tissue repair process: a literature review. JORDI — Journal of Oral Diagnosis. 2017; 2: 1–6. DOI: 10.5935/2525-5711.20170032</mixed-citation><mixed-citation xml:lang="en">Ner J., Lomba E., Karam A.M., De Almeda Reis S.R., Teixeira Marchionni A., Pexoto Meidrado A. Ozone therapy inﬂ uence in the tissue repair process: a literature review. JORDI — Journal of Oral Diagnosis. 2017; 2: 1–6. DOI: 10.5935/2525-5711.20170032</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kiesler P., Fuss I.J., Strober W. Experimental Models of Inﬂ ammatory Bowel Diseases. Cell Mol. Gastroenterol. Hepatol. 2015; 1(2): 154–170. DOI: 10.1016/j.jcmgh.2015.01.006</mixed-citation><mixed-citation xml:lang="en">Kiesler P., Fuss I.J., Strober W. Experimental Models of Inﬂ ammatory Bowel Diseases. Cell Mol. Gastroenterol. Hepatol. 2015; 1(2): 154–170. DOI: 10.1016/j.jcmgh.2015.01.006</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hoving J.C., Keeton R., Höft M.A., Ozturk M., Otieno-Odhiambo P., Brombacher F. IL-4 Receptor-Alpha Signalling of Intestinal Epithelial Cells, Smooth Muscle Cells, and Macrophages Plays a Redundant Role in Oxazolone Colitis. Mediators. Inﬂ amm. 2020; 2020: 4361043. DOI: 10.1155/2020/4361043</mixed-citation><mixed-citation xml:lang="en">Hoving J.C., Keeton R., Höft M.A., Ozturk M., Otieno-Odhiambo P., Brombacher F. IL-4 Receptor-Alpha Signalling of Intestinal Epithelial Cells, Smooth Muscle Cells, and Macrophages Plays a Redundant Role in Oxazolone Colitis. Mediators. Inﬂ amm. 2020; 2020: 4361043. DOI: 10.1155/2020/4361043</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Varma A., Weinstein J., Seabury J., Rosero S., Wagner E., Zizzi C., Luebbe E., Dilek N., McDermott M., Heatwole J., Saubermann L., Temple L., Rogoff S., Heatwole C. Patient-Reported Impact of Symptoms in Crohn’s Disease. Am. J. Gastroenterol. 2022; 117(12): 2033–2045. DOI: 10.14309/ajg.0000000000001954</mixed-citation><mixed-citation xml:lang="en">Varma A., Weinstein J., Seabury J., Rosero S., Wagner E., Zizzi C., Luebbe E., Dilek N., McDermott M., Heatwole J., Saubermann L., Temple L., Rogoff S., Heatwole C. Patient-Reported Impact of Symptoms in Crohn’s Disease. Am. J. Gastroenterol. 2022; 117(12): 2033–2045. DOI: 10.14309/ajg.0000000000001954</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Vart G., Banzi R., Minozzi S. Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis. Prev. Med. 2012; 55(2): 87–92. DOI: 10.1016/j.ypmed.2012.05.006</mixed-citation><mixed-citation xml:lang="en">Vart G., Banzi R., Minozzi S. Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis. Prev. Med. 2012; 55(2): 87–92. DOI: 10.1016/j.ypmed.2012.05.006</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Osikov M., Boyko M., Fedosov A., Ilyinykh M. Effectiveness of Experimental Colitis Therapy with Original Vitamin D3 Rectal Suppositories. International Journal of Biomedicine. 2022; 12(1): 124–133. DOI: 10.21103/article12(1)_oa13</mixed-citation><mixed-citation xml:lang="en">Osikov M., Boyko M., Fedosov A., Ilyinykh M. Effectiveness of Experimental Colitis Therapy with Original Vitamin D3 Rectal Suppositories. International Journal of Biomedicine. 2022; 12(1): 124–133. DOI: 10.21103/article12(1)_oa13</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Осиков М.В., Давыдова Е.В., Бойко М.С., Бакеева А.Е., Кайгородцева Н.В., Галеева И.Р., Федосов А.А., Ильиных М.А., Воргова Л.В. Особенности свободнорадикального окисления в толстом кишечнике при язвенном колите и болезни Крона. Вестник РГМУ. 2020; 3: 63–70. DOI: 10.24075/vrgmu.2020.027</mixed-citation><mixed-citation xml:lang="en">Osikov M.V., Davydova E.V., Boyko M.S., Bakeeva A.E., Kaygorodtseva N.V., Galeeva I.R., Fedosov A.A., Ilyinyh M.A., Vorgova L.V. Aspects of free radical oxidation in the large bowel in ulcerative colitis and Crohn’s disease. Vestnik RGMU. 2020; 3: 63–70 (In Russ.). DOI: 10.24075/vrgmu.2020.027</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Galiè M., Covi V., Tabaracci G., Malatesta M. The Role of Nrf2 in the Antioxidant Cellular Response to Medical Ozone Exposure. Int. J. Mol. Sci. 2019; 20(16): 4009. DOI: 10.3390/ijms20164009</mixed-citation><mixed-citation xml:lang="en">Galiè M., Covi V., Tabaracci G., Malatesta M. The Role of Nrf2 in the Antioxidant Cellular Response to Medical Ozone Exposure. Int. J. Mol. Sci. 2019; 20(16): 4009. DOI: 10.3390/ijms20164009</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Cenci A., Macchia I., La Sorsa V., Sbarigia C., Di Donna V., Pietraforte D. Mechanisms of Action of Ozone Therapy in Emerging Viral Diseases: Immunomodulatory Effects and Therapeutic Advantages With Reference to SARS-CoV-2. Front. Microbiol. 2022; 13: 871645. DOI: 10.3389/fmicb.2022.871645</mixed-citation><mixed-citation xml:lang="en">Cenci A., Macchia I., La Sorsa V., Sbarigia C., Di Donna V., Pietraforte D. Mechanisms of Action of Ozone Therapy in Emerging Viral Diseases: Immunomodulatory Effects and Therapeutic Advantages With Reference to SARS-CoV-2. Front. Microbiol. 2022; 13: 871645. DOI: 10.3389/fmicb.2022.871645</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Burke R., Chu C., Zhou G.D., Putluri V., Putluri N., Stading R.E., Couroucli X., Lingappan K., Moorthy B. Role of Human NADPH Quinone Oxidoreductase (NQO1) in Oxygen-Mediated Cellular Injury and Oxidative DNA Damage in Human Pulmonary Cells. Oxid. Med. Cell Longev. 2021; 2021: 5544600. DOI: 10.1155/2021/5544600</mixed-citation><mixed-citation xml:lang="en">Burke R., Chu C., Zhou G.D., Putluri V., Putluri N., Stading R.E., Couroucli X., Lingappan K., Moorthy B. Role of Human NADPH Quinone Oxidoreductase (NQO1) in Oxygen-Mediated Cellular Injury and Oxidative DNA Damage in Human Pulmonary Cells. Oxid. Med. Cell Longev. 2021; 2021: 5544600. DOI: 10.1155/2021/5544600</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Зинчук В.В., Билецкая Е.С. Кислородзависимые механизмы физиологического действия озона (обзор). Журнал медико-биологических исследований. 2019; 7(2): 216–227. DOI: 10.17238/issn2542-1298.2019.7.2.216</mixed-citation><mixed-citation xml:lang="en">Zinchuk V.V., Biletskaya E.S. Oxygen-dependent mechanisms of the physiological action of ozone (review). Zhurnal Mediko-Biologicheskikh Issledovanii. 2019; 7(2): 216–227 (In Russ.). DOI: 10.17238/issn2542-1298.2019.7.2.216</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Clavo B., Santana-Rodríguez N., Llontop P., Gutiérrez D., Suárez G, López L., Rovira G., Martínez-Sánchez G., González E., Jorge I.J., Perera C., Blanco J., Rodríguez-Esparragón F. Ozone Therapy as Adjuvant for Cancer Treatment: Is Further Research Warranted? Evid. Based. Complement. Alternat. Med. 2018; 2018: 7931849. DOI: 10.1155/2018/7931849</mixed-citation><mixed-citation xml:lang="en">Clavo B., Santana-Rodríguez N., Llontop P., Gutiérrez D., Suárez G, López L., Rovira G., Martínez-Sánchez G., González E., Jorge I.J., Perera C., Blanco J., Rodríguez-Esparragón F. Ozone Therapy as Adjuvant for Cancer Treatment: Is Further Research Warranted? Evid. Based. Complement. Alternat. Med. 2018; 2018: 7931849. DOI: 10.1155/2018/7931849</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Martínez-Sánchez G., Schwartz A., Donna V.D. Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19. Antioxidants (Basel). 2020; 9(5): 389. DOI: 10.3390/antiox9050389</mixed-citation><mixed-citation xml:lang="en">Martínez-Sánchez G., Schwartz A., Donna V.D. Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19. Antioxidants (Basel). 2020; 9(5): 389. DOI: 10.3390/antiox9050389</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Manoto S.L., Maepa M.J., Motaung S.K. Medical ozone therapy as a potential treatment modality for regeneration of damaged articular cartilage in osteoarthritis. Saudi. J. Biol. Sci. 2018; 25(4): 672–679. DOI: 10.1016/j.sjbs.2016.02.002</mixed-citation><mixed-citation xml:lang="en">Manoto S.L., Maepa M.J., Motaung S.K. Medical ozone therapy as a potential treatment modality for regeneration of damaged articular cartilage in osteoarthritis. Saudi. J. Biol. Sci. 2018; 25(4): 672–679. DOI: 10.1016/j.sjbs.2016.02.002</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Sauaia A., Moore F.A., Moore E.E. Postinjury Inﬂ ammation and Organ Dysfunction. Crit. Care. Clin. 2017; 33(1): 167–191. DOI: 10.1016/j.ccc.2016.08.006</mixed-citation><mixed-citation xml:lang="en">Sauaia A., Moore F.A., Moore E.E. Postinjury Inﬂ ammation and Organ Dysfunction. Crit. Care. Clin. 2017; 33(1): 167–191. DOI: 10.1016/j.ccc.2016.08.006</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
